Search for Clinical Trial Results

Sponsored By

Cystadenocarcinoma - 15 Studies Found

Status Study
Active, not recruiting Study Name: Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer
Condition:
  • Borderline Ovarian Mucinous Tumor
  • Ovarian Mucinous Cystadenocarcinoma<
    Date: 2010-03-04
    Interventions:
    • Biological: Bevacizumab Given

Terminated Study Name: Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors
Condition:
  • Adenocarcinoma of the Pancreas
  • Adenocarcinoma of the Stomach
  • Drug: veliparib Given PO
Completed Study Name: Papillary Serous Carcinoma of the Endometrium
Condition: Endometrial Cancer
Date: 2007-08-09
Interventions:
  • Drug: Paclitaxel 50 mg/m^2 IV

Completed Study Name: A Study of Radiation Therapy and Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma
Condition: Uterine Cancer
Date: 2005-10-03
Interventions:
  • Drug: Carboplatin and Paclitaxel and Pelvic Radiation Therapy

Completed Study Name: Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma
Condition: Uterine Cancer
Date: 2007-07-23
Interventions:
  • Drug: Imatinib Mesylate

Not yet recruiting Study Name: Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation Therapy in Treating Patients With Stage IIIC-IV Uterine Cancer
Condition:
  • Endometrial Serous Adenocarcinoma
  • Stage IIIA Uterine Corpus Can
    Date: 2014-04-10
    Interventions:
    • Drug: Paclitaxel Given IV
Completed Study Name: To Assess the Safety of Continuous IV Administration of Plerixafor in Patients With Advanced Pancreatic, Ovarian and Colorectal Cancers
Condition:
  • Pancreatic Adenocarcinoma Metastatic
  • Ovarian Serous Adenocarcinoma Date: 2014-07-01
    Interventions: Drug: Plerixafor A continuous 7 day intravenous infusion, starting at a dose of 20 ug/kg/hr, and subsequ
Completed Study Name: Phase II ABT-888 With Cyclophosphamide
Condition:
  • Ovarian Cancer
  • Primary Peritoneal Cancer
  • Drug: ABT-888 PARP enzymes are
Recruiting Study Name: Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer
Condition:
  • Micropapillary Serous Carcinoma
  • Ovarian S
    Date: 2014-03-28
    Interventions:
    • Other: Laboratory Biomarker Analysis

Completed Study Name: Paclitaxel in Treating Patients With Refractory or Recurrent Endometrial Cancer
Condition:
Date: 2025-11-04
Next >>>